Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. Co. is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. Co.'s pipeline includes ARQ-255, ARQ-252, and ARQ-234. We show 25 historical shares outstanding datapoints in our coverage of ARQT's shares outstanding history.
Understanding the changing numbers of ARQT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ARQT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ARQT by allowing them to research ARQT shares outstanding history
as well as any other stock in our coverage universe. |
Free ARQT Email Alerts:
Video: Shares Outstanding Importance
